Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MNTL
Upturn stock ratingUpturn stock rating

Tema Neuroscience and Mental Health ETF (MNTL)

Upturn stock ratingUpturn stock rating
$22.35
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

04/01/2025: MNTL (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Outstanding Performance

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Analysis of Past Performance

Type ETF
Historic Profit 0.2%
Avg. Invested days 70
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
ETF Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 04/01/2025

Key Highlights

Volume (30-day avg) 733
Beta -
52 Weeks Range 22.35 - 27.39
Updated Date 04/1/2025
52 Weeks Range 22.35 - 27.39
Updated Date 04/1/2025

ai summary icon Upturn AI SWOT

Tema Neuroscience and Mental Health ETF

stock logo

ETF Overview

overview logo Overview

The Tema Neuroscience and Mental Health ETF (MENT) focuses on investing in companies that are developing treatments, technologies, and services related to neuroscience and mental health. It aims to capture growth opportunities in this emerging healthcare sector.

reliability logo Reputation and Reliability

Tema ETFs are relatively new to the market, but their focus on thematic investing has garnered attention. It's crucial to monitor their performance and track record over time.

reliability logo Management Expertise

The ETF's management team possesses experience in thematic investing and healthcare sectors, providing valuable insight into identifying promising companies in the neuroscience and mental health space.

Investment Objective

overview logo Goal

To provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Tema Neuroscience and Mental Health Index.

Investment Approach and Strategy

Strategy: The ETF tracks an index comprised of companies involved in the neuroscience and mental health industry, focusing on those developing or utilizing treatments and technologies in this field.

Composition The ETF primarily holds stocks of companies in the healthcare, biotechnology, and technology sectors that are involved in the treatment, research, and support of mental health and neurological disorders.

Market Position

Market Share: Data regarding MENT's specific market share is limited due to the niche and nascent nature of the neuroscience and mental health ETF market.

Total Net Assets (AUM): Precise AUM data should be sourced from official financial data providers.

Competitors

overview logo Key Competitors

Competitive Landscape

The competitive landscape for neuroscience and mental health ETFs is currently limited due to the specialization of the sector. As the sector grows, increased competition from broader healthcare or biotech ETFs is possible. MENT's advantages lie in its targeted approach and potential for high growth, while a disadvantage is the inherent risk associated with investing in a niche sector.

Financial Performance

Historical Performance: Historical performance data should be sourced from official financial data providers and analyzed over different time periods (e.g., 1 year, 3 years, 5 years).

Benchmark Comparison: To assess the ETF's effectiveness, its performance should be compared to relevant healthcare or biotechnology indices.

Expense Ratio: Precise expense ratio data should be sourced from official financial data providers.

Liquidity

Average Trading Volume

Assess the average trading volume through official financial data providers to understand the liquidity of the ETF.

Bid-Ask Spread

Obtain the bid-ask spread from financial data providers to determine the cost of trading the ETF.

Market Dynamics

Market Environment Factors

The ETF is affected by factors such as advancements in neuroscience, regulatory changes in healthcare, and the overall growth of the biotechnology and pharmaceutical industries.

Growth Trajectory

Monitor changes in strategy, holdings, and market focus to understand the growth trends of the ETF, as well as overall market changes.

Moat and Competitive Advantages

Competitive Edge

MENT's competitive edge lies in its focused approach on the neuroscience and mental health sector, capitalizing on the increasing awareness and investment in mental health solutions. Its investment strategy is targeted towards companies developing innovative therapies and technologies. The ETF benefits from the growing demand for mental health treatments and the limited number of specialized investment vehicles in this area.

Risk Analysis

Volatility

Assess the ETF's historical volatility by analyzing its price fluctuations and beta.

Market Risk

The ETF is exposed to market risks related to the healthcare and biotechnology sectors, including regulatory hurdles, clinical trial failures, and competition from other companies.

Investor Profile

Ideal Investor Profile

The ideal investor for MENT is someone with a high risk tolerance and an interest in the healthcare and biotechnology sectors. It's appropriate for those seeking exposure to the growing field of neuroscience and mental health.

Market Risk

MENT is suitable for long-term investors who believe in the growth potential of the neuroscience and mental health industry. It's not recommended for risk-averse investors due to the volatility associated with the sector.

Summary

The Tema Neuroscience and Mental Health ETF (MENT) offers focused exposure to companies at the forefront of neuroscience and mental health. It is suitable for long-term investors with high risk tolerance and interest in healthcare. The ETF is subject to market risks related to regulations, clinical trials, and competition. Its performance should be continuously compared against its benchmark and other healthcare indices, and the fund is suitable for investors who see potential growth in the neuroscience and mental health sector.

Similar Companies

  • IBB
  • XBI
  • XLV

Sources and Disclaimers

Data Sources:

  • Official ETF provider website
  • Financial data providers (e.g., Bloomberg, Reuters)
  • SEC filings

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual circumstances and consultation with a financial advisor. Past performance is not indicative of future results.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Tema Neuroscience and Mental Health ETF

Exchange NASDAQ
Headquaters -
IPO Launch date -
CEO -
Sector -
Industry -
Full time employees -
Website
Full time employees -
Website

Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The fund is non-diversified.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​